&lt;p&gt;LINC02381 Promoted Cell Viability and Migration via Targeting miR-133b in Cervical Cancer Cells&lt;/p&gt;

2021

IJMS

Parkinson’s disease (PD) is a neurodegenerative disorder that affects 1% of the population over the age of 60. Diabetes Mellitus (DM) is a metabolic disorder that affects approximately 25% of adults over the age of 60. Recent studies showed that DM increases the risk of developing PD. The link between DM and PD has been discussed in the literature in relation to different mechanisms including mitochondrial dysfunction, oxidative stress, and protein aggregation. In this paper, we review the common microRNA (miRNA) biomarkers of both diseases. miRNAs play an important role in cell differentiation, development, the regulation of the cell cycle, and apoptosis. They are also involved in the pathology of many diseases. miRNAs can mediate the insulin pathway and glucose absorption. miRNAs can also regulate PD-related genes. Therefore, exploring the common miRNA biomarkers of both PD and DM can shed a light on how these two diseases are correlated, and targeting miRNAs is a potential therapeutic opportunity for both diseases.

Section: Micrornamentioning

confidence: 99%

MicroRNAs, Parkinson’s Disease, and Diabetes Mellitus

2021

IJMS

“…Their study focused on B-cell chronic lymphocytic leukemia (B-CLL) [ 40 ]. After that, many studies showed that miRNAs can initiate carcinogenesis or drive the progression of cancer [ 41 , 42 , 43 , 44 ]. The miR-527 acts as an oncogenic miRNA in esophageal squamous cell carcinoma by directly targeting PHLPP2 [ 42 ].…”

Section: Micrornamentioning

confidence: 99%

“…The miR-527 acts as an oncogenic miRNA in esophageal squamous cell carcinoma by directly targeting PHLPP2 [ 42 ]. LINC02381 acts as an oncogene in the development of cervical cancer that promotes cell viability and metastasis via miR-133b [ 43 ]. The miR-1193 plays a tumor inhibitory role in cervical cancer by directly targeting CLDN7 [ 44 ].…”

Section: Micrornamentioning

confidence: 99%

MicroRNAs and Apoptosis in Colorectal Cancer

2020

IJMS

Colorectal cancer (CRC) is the third leading cause of cancer death in the world, and its incidence is rising in developing countries. Treatment with 5-Fluorouracil (5-FU) is known to improve survival in CRC patients. Most anti-cancer therapies trigger apoptosis induction to eliminate malignant cells. However, de-regulated apoptotic signaling allows cancer cells to escape this signaling, leading to therapeutic resistance. Treatment resistance is a major challenge in the development of effective therapies. The microRNAs (miRNAs) play important roles in CRC treatment resistance and CRC progression and apoptosis. This review discusses the role of miRNAs in contributing to the promotion or inhibition of apoptosis in CRC and the role of miRNAs in modulating treatment resistance in CRC cells.

“…Meanwhile, LINC02381 inhibits gastric cancer progression and metastasis through regulating wnt signaling pathway [46]. However, LINC02381 functions as a cancer-promoting gene to promote cell migration and viability by regulating mir-133b / RhoA in cervical cancer [47].…”

Section: Based On the Strati Cation Of Clinical Variables The Correlmentioning

confidence: 99%

A Novel Ferroptosis-related Lncrna Prognostic Signature for Colorectal Cancer by Bioinformatics Analysis

Yang

Zhang

et al. 2021

Preprint

Background: Recently, extensive studies have shown that ferroptosis in cancer treatment has been increasingly confirmed. The current study aims to construct a robust ferroptosis-related lncRNAs signature prediction model of colorectal cancer (CRC) patients by bioinformatics analysisMethods: The transcriptome data were abstracted from The Cancer Genome Atlas (TCGA). Differentially expressed lncRNAs were screened by comparing 568 CRC tissues with 44 adjacent non-CRC tissues. Univariate Cox regression, lasso regression, multivariate Cox regression were conducted to design a ferroptosis-related lncRNA signature. This signature’s prognosis was verified by the log-rank test of Kaplan-Meier curve and the area under curve (AUC) of receiver operating characteristic (ROC) in train set, test set, and entire set. Furthermore, univariate and multivariate Cox regression were used to analyze its independent prognostic ability. The relationship of the ferroptosis-linked lncRNAs' expression and clinical variables was demonstrated by Wilcoxon rank-sum test and Kruskal-Wallis test. Gene set enrichment analysis (GSEA) was performed to signaling pathways it may involve.Results: 2541 differentially expressed lncRNAs were screened, of which 439 are ferroptosis-related lncRNAs. A seven ferroptosis-related lncRNAs (AC005550.2, LINC02381, AL137782.1, C2orf27A, AC156455.1, AL354993.2, AC008760.1) prognostic signature was constructed, validated and evaluated. This model's prognosis in the high-risk group is obviously worse than that of the low-risk group in train set, test set, and entire set. The AUC of ROC predicting the three years survival in the train set, test set, and entire set was 0.796, 0.715, and 0.758, respectively. Moreover, the designed molecular signature was found to be an independent prognostic variable. Compared to clinical variables, this signature's ROC curves demonstrated the second largest AUC value (0.737). The expression of these lncRNAs and the lncRNA signature are related to distant metastasis, Lymph-node status, clinical stage, T stage, KRAS mutation, BRAF mutation, MMR status, and perineural invasion. Finally, GSEA analysis results show that the signature is involved in six metabolism-related pathways.Conclusion: The current study constructed, validated, and evaluated a seven ferroptosis-related lncRNA signature which can independently be used to predict the prognosis of CRC patients, and it may become a new therapeutic target.